Cover Image

Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Background. Atopic dermatitis (AD) is a complex, chronic, inflammatory skin disease characterized by pruritic, intense itching, and eczematous lesions affecting about 25% of children and 2% to 3% of adults worldwide. Abrocitinib is a selective inhibitor of Janus kinase-1 (JAK1) enzyme inhibiting the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hammad Ali Fadlalmola (Author), Muayad Saud Albadrani (Author), Amal Mohamed Elhusein (Author), Wahieba E. Mohamedsalih (Author), Veerabhadra D. S. Swamy (Author), Daniel Mon Mamanao (Author)
Format:	Book
Published:	Hindawi Limited, 2021-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Research progress on abrocitinib in the treatment of moderate and severe atopic dermatitis
by: Xu ZHU, et al.
Published: (2023)

Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: Meta-analysis
by: Ling Li, et al.
Published: (2023)

Effect of abrocitinib and dupilumab on eosinophil levels in patients with moderate‐to‐severe atopic dermatitis
by: Delphine Staumont‐Sallé, et al.
Published: (2023)

Preliminary experience with abrocitinib in severe atopic dermatitis
by: Silvia Ferrucci, et al.
Published: (2024)

Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
by: Helena Iznardo, et al.
Published: (2023)

Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice
by: Melinda J. Gooderham, et al.
Published: (2023)

Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study - il AD (Italian landscape atopic dermatitis)
by: Luigi Gargiulo, et al.
Published: (2024)

Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
by: Melinda J. Gooderham, MSc, MD, FRCPC, et al.
Published: (2021)

Kinetic‐Pharmacodynamic Model of Platelet Time Course in Patients With Moderate‐to‐Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib
by: Elena Soto, et al.
Published: (2020)

A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
by: Jiahui Zhao, PhD, MD, et al.
Published: (2022)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
by: Miguel Nogueira, et al.
Published: (2021)

Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc analysis of the JADE clinical trials
by: Melinda J. Gooderham, et al.
Published: (2023)

Once-Daily Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults and Adolescents Aged 12 Years and Over: A Short Review of Current Clinical Perspectives
by: Niculet E, et al.
Published: (2022)

Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations
by: Melinda J. Gooderham, et al.
Published: (2024)

The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data
by: Napolitano M, et al.
Published: (2021)

Abrocitinib may improve itch and quality of life in patients with itch‐dominant atopic dermatitis
by: Jonathan I. Silverberg, et al.
Published: (2024)

Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis
by: April W. Armstrong, et al.
Published: (2024)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
by: Novin Nezamololama, et al.
Published: (2020)

Unveiling abrocitinib: A thorough examination of the 2022 USFDA-approved treatment for atopic dermatitis (AD)
by: Daniela Bermeo Grajales, et al.
Published: (2023)

Efficacy of dupilumab in moderate and severe atopic dermatitis
by: Stephan Weidinger, et al.
Published: (2023)

Expert opinion on management of moderate-to-severe atopic dermatitis in Qatar
by: Martin Steinhoff, et al.
Published: (2023)

Association of moderate-severe atopic dermatitis with dental anomalies
by: Sean Y Tan, et al.
Published: (2022)

Patient Preferences in the Treatment of Moderate-to-severe Atopic Dermatitis
by: Mahreen Ameen, et al.
Published: (2024)

A Case of Perioral Dermatitis Successfully Treated with Abrocitinib
by: Teng Y, et al.
Published: (2023)

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
by: Maria Esposito, MD, et al.
Published: (2023)

Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients
by: Rachael C. Saporito, et al.
Published: (2016)

Advances in systemic treatment for adults with moderate-to-severe atopic dermatitis
by: Yung-Tsu Cho, et al.
Published: (2019)

Biologic Therapy of Moderate and Severe Forms of Atopic Dermatitis in Children
by: Nikolay N. Murashkin, et al.
Published: (2020)

Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series
by: Adrien Mareschal, et al.
Published: (2020)

Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review
by: Yuliya Lytvyn, et al.
Published: (2022)

Efficacy and safety of dupilumab in adult moderate-to-severe atopic dermatitis: An update narrative literature review
by: Magdalini Kreouzi, et al.
Published: (2022)

Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
by: Hagino T, et al.
Published: (2023)

Dupilumab‐associated head and neck dermatitis: Rapid response with abrocitinib treatment
by: Adinia Santosa, et al.
Published: (2024)

Is Dupilumab a chance for patients with moderate to severe atopic dermatitis? Literature review
by: Paweł Iwańczuk
Published: (2024)

Real‐world effectiveness and safety of dupilumab in patients with moderate and severe atopic dermatitis: 2‐year experience
by: Chisako Fujiwara, et al.
Published: (2023)

Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis
by: Jinger Lin, et al.
Published: (2024)

Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial
by: Carsten Flohr, et al.
Published: (2023)

Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry
by: Esmé Kamphuis, et al.
Published: (2024)

Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis
by: Awosika O, et al.
Published: (2018)

Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus
by: Jose J. Pereyra-Rodriguez, et al.
Published: (2023)